<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28423129</article-id><article-id pub-id-type="pmc">5382908</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2016-0065</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Totally Percutaneous Access Using Perclose Proglide for Endovascular
Treatment of Aortic Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saadi</surname><given-names>Eduardo Keller</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Saadi</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Saadi</surname><given-names>Rodrigo</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tagliari</surname><given-names>Ana Paula</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mastella</surname><given-names>Bernardo</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Hospital de Cl&#x000ed;nicas de Porto Alegre (HCPA), Universidade
Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</aff><aff id="aff2"><label>2</label>Universidade Luterana do Brasil (ULBRA), Canoas, RS, Brazil.</aff><aff id="aff3"><label>3</label>Pontif&#x000ed;cia Universidade Cat&#x000f3;lica do Rio Grande do Sul
(PUCRS), Porto Alegre, RS, Brazil.</aff><aff id="aff4"><label>4</label>Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS,
Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Eduardo Keller Saadi, Rua Ramiro Barcelos,
2350 - Porto Alegre, RS, Brazil - Zip code: 90035-903. E-mail:
<email>esaadi@terra.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2017</year></pub-date><volume>32</volume><issue>1</issue><fpage>43</fpage><lpage>48</lpage><history><date date-type="received"><day>04</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>1</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate our experience following the introduction of a percutaneous
program for endovascular treatment of aortic diseases using Perclose
Proglide&#x000ae; assessing efficacy, complications and identification of
potential risk factors that could predict failure or major access site
complications.</p></sec><sec><title>Methods</title><p>A retrospective cohort study during a two-year period was performed. All the
patients submitted to totally percutaneous endovascular repair (PEVAR) of
aortic diseases and transcatheter aortic valve implantation since we started
the total percutaneous approach with the preclosure technique from November
2013 to December 2015 were included in the study. The primary endpoint was
major ipsilateral access complication, defined according to PEVAR trial.
</p></sec><sec><title>Results</title><p>In a cohort of 123 patients, immediate technical success was obtained in 121
(98.37%) patients, with only two (0.82%) cases in 242 vascular access sites
that required intervention immediately after the procedure. Pairwise
comparisons revealed increased major access complication among patients with
&#x0003e;50% common femoral artery (CFA) calcification <italic>vs.</italic> none
(<italic>P</italic>=0.004) and &#x0003e; 50% CFA calcification
<italic>vs.</italic> &#x0003c; 50% CFA calcification
(<italic>P</italic>=0.002). Small artery diameter (&#x0003c;6.5 mm) also
increased major access complication compared to bigger diameters (&#x0003e; 6.5
mm) (<italic>P</italic>=0.027).</p></sec><sec><title>Conclusion</title><p>The preclosure technique with two Perclose Proglide&#x000ae; for PEVAR is safe
and effective. Complications occur more often in patients with unfavorable
access site anatomy and the success rate can be improved with proper patient
selection.</p></sec></abstract><kwd-group><kwd>Aortic Diseases</kwd><kwd>Aortic Aneurysm</kwd><kwd>Endovascular Procedures</kwd><kwd>Femoral Artery</kwd><kwd>Suture Techniques/Instrumentation</kwd></kwd-group></article-meta></front><body><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ACT<break/> CFA<break/> CEVAR<break/> EVAR<break/>
ICU<break/> PEVAR<break/> SD<break/> SEVAR<break/> SPSS<break/>
TAVI<break/> TEVAR</td><td align="left" rowspan="1" colspan="1">= Activated clotting time &#x000a0;<break/> = Common femoral artery
&#x000a0;<break/> = Common femoral artery endovascular repair&#x000a0;<break/> =
Endovascular aneurysm repair &#x000a0;<break/> = Intensive care unit&#x000a0;<break/> =
Percutaneous endovascular repair &#x000a0;<break/> = Standard deviation
&#x000a0;<break/> = Surgical endovascular repair &#x000a0;<break/> = Statistical Package
for Social Sciences &#x000a0;<break/> = Transcatheter aortic valve implantation
&#x000a0;<break/> = Thoracic endovascular aortic repair</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Endovascular treatment has been the first option of many thoracic and abdominal
aortic diseases, as well as transcatheter aortic valve implantation (TAVI) in the
last years. The access is usually the surgical exposure of the common femoral
arteries (CFA) to introduce the delivery system.</p><p>Arteriotomy closure devices were introduced in 1995 to decrease vascular
complications and reduce the time to hemostasis and ambulation. Subsequently,
several generations of passive and active arteriotomy closure devices have been
introduced that incorporate suture, collagen plug, nitinol clip and other mechanisms
to achieve hemostasis<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. In 1999
there was the advent of preclosure technique advocated by Haas et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>Subsequently, the preclosure technique was proven to be safe for bigger sheaths and
then, the totally percutaneous endovascular repair (PEVAR) approach from the femoral
arteries has been applied as an alternative to surgical cutdown<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Even being less invasive than
surgical cutdown at the vascular access, the use of total percutaneous approach has
not gained broad acceptance.</p><p>Few studies have reported the results and our aim is to verify the safety and
efficacy of this technique in a clinical series.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Registry of consecutive patients submitted to percutaneous endovascular procedures to
treat aortic diseases identified from our prospectively maintained database. This
clinical observational study was approved by the research and ethics committee of
our institution, under the number 16-0124.</p><p>All the patients submitted to complete percutaneous treatment for aortic diseases and
TAVI since we started the total percutaneous approach with the preclosure technique
from November 2013 to December 2015 were included in the study that analyzed major
and minor access site complications and correlate with some potential risk
factors.</p><p>A major ipsilateral access complication was defined according to PEVAR trial: 1) an
access site vascular injury requiring repair, 2) new onset of lower-extremity
ischemia necessitating surgical or percutaneous intervention, 3) access site-related
bleeding necessitating transfusion, 4) access site-related infection necessitating
antibiotics, drainage or prolonged hospitalization and 5) acute pseudoaneurysm.</p><p>A secondary endpoint of minor ipsilateral access site vascular sequelae was also
evaluated. Minor sequelae included 1) pseudoaneurysm/arteriovenous fistula, 2)
hematomas &#x0003e; 6 cm, 3) post-discharge bleeding necessitating &#x0003e; 30 minutes to
reach hemostasis, and 4) deep venous thrombosis. Another secondary endpoint
evaluated was late follow-up by angiotomography in the 3<sup>rd</sup> month and then
yearly as arterial thrombosis, arterial dissection, pseudoaneurysm, stenosis &#x0003e;
30%, arteriovenous fistula and hematoma. Any percutaneous accesses with introducer
&#x02265; 12 F were analyzed independently as access site.</p><p>The exclusion criteria for the study was incomplete data collection or lost
follow-up. There was just one patient excluded from the study that died after TAVI
due to acute coronary occlusion and all other consecutive patients in that period
were included.</p><sec><title>Technique for Vascular Closure Device Implantation</title><p>All the procedures were performed by the same operator with the use of the
Perclose Proglide&#x000ae; (Abbott Vascular, CA, USA) device. Previous training
in a simulator and 50 procedures were performed delivering a single perclose in
sheaths less than 9 F. Only then, the use of the preclose technique was started
for bigger introducer systems.</p><p>The procedures were performed under general, regional or local anesthesia,
depending on the patient evaluation by the surgeon and anesthetist. The puncture
site was evaluated by preoperative angiotomography, in order to identify the
bifurcation level, the size, tortuosity and the grade of calcification of the
CFA and external iliac arteries. After a small incision in the skin (2 mm) with
an 11 blade, the CFA was punctioned with an 18 needle using the Seldinger
technique, avoiding the posterior wall. No ultrasound was used to guide the
puncture. A short 6 F introducer was inserted first in the right CFA. A sharp
dilatation around the sheath with the dilator inside was performed with a Kelly
in the subcutaneous tissue, in order to facilitate the knots tying at the end of
the procedure. Two Percloses Proglide&#x000ae; were then inserted through a short
0.035 wire, starting from the surgeon&#x02019;s side (right) to the left of the patient.
The first Perclose Proglide&#x000ae; was positioned at 11 o&#x02019;clock and the second
one at 1 o&#x02019;clock. The 3-0 prolene of the device was gently repaired in moist
gauze without tension. After the insertion of the second vascular closure
device, a 7 F short sheath was inserted to avoid bleeding. The same step was
done in the left femoral artery. At this time, heparin was given at 1 mg/kg to
keep the activated clotting time (ACT) around 250 seconds.</p><p>The endovascular procedure was carried out as usual with the bigger sheaths
insertion and endoprosthesis implantation. At the end of the procedure, the
assistant compressed manually the puncture site as the surgeon removed the
introducer, leaving a hydrophilic wire in place, while the knots were tied,
starting from the right towards the left. The first knot (right) approximates
the artery pulling the blue suture thread. If there was no pulsatile bleeding,
the wire was removed and the knot pushed to the artery with the trimmer, tied
with the white thread and cut. The second knot (left) was then tied. The same
step was done in the left femoral artery, starting from the right side of the
patient. Heparin was reversed half dose and manual compression was maintained
for at least 5 minutes. If any bleeding was noted, further compression was
applied.</p></sec><sec><title>Success Definition and Follow-Up by Angiotomography</title><p>Immediate success was defined as good vascular closure device (Perclose
Proglide&#x000ae;) delivery with adequate knot tightening and closure of the CFA
without any bleeding, vascular occlusion, open conversion or further
endovascular intervention for artery repair in the first 30 days after the
procedure. Blood transfusion, groin hematoma or lymphocele were also
evaluated.</p><p>All the patients were followed up clinically and with an angiotomography of the
aortic correction and the vascular access site during three months and then,
yearly to evaluate late access-related complications. The images were analyzed
independently and separately by a radiologist and a surgeon. Complications
considered at the access site by angiotomography were: arterial thrombosis,
dissection, pseudoaneurysm, stenosis &#x0003e; 30% and arteriovenous fistula. The
absence of any of these complications was considered late success.</p></sec><sec><title>Statistical Analysis</title><p>The software Statistical Package for Social Sciences (SPSS) 18.0 was used for
data processing and statistical analysis.</p><p>Continuous data were presented as mean &#x000b1; standard deviation (SD).
Categorical data were described as number and percentages. Student&#x02019;s t-test was
used to compare continuous data and Chi-square test to compare categorical data
in order to evaluate success and complications. Binary logistic regression and
one-way ANOVA analysis were used to detect outcome predictors. A
<italic>P</italic> value &#x0003c;0.05 was considered statistically
significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Demographic and procedure characteristics are presented in <xref ref-type="table" rid="t1">Tables 1</xref> to <xref ref-type="table" rid="t3">3</xref>,
respectively. Immediate technical success was obtained in 121 (98.37%) patients,
with only 2 (0.82%) cases in 242 vascular access sites that required intervention
immediately after the procedure (<xref ref-type="table" rid="t4">Table 4</xref>). In
both patients, severe ischemia was detected by physical examination in the hybrid
room and prompt surgical approach of the femoral arteries. One patient had thoracic
endovascular aortic repair (TEVAR) with a 20 F sheath and the other an endovascular
aneurysm repair (EVAR) with an 18 F introducer. They were female, with small (&#x0003c;
6.5 mm) and calcified (&#x0003e; 50%) access vessels. During the surgical exposure, a
plaque obstruction was observed. In one case, a resection with a direct end-to-end
anastomosis was done in the CFA and, in the other patient, a 7 mm
polytetrafluoroethylene graft was interposed between external iliac and CFA. Both
patients had a good and uneventful postoperative course.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic characteristic.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">Mean (interval)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patient</td><td align="center" rowspan="1" colspan="1">123 (100)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">76.80 (43 &#x02013; 95)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">76 (61.8)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">47 (38.2)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypertension</td><td align="center" rowspan="1" colspan="1">95 (77.2)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetes</td><td align="center" rowspan="1" colspan="1">39 (31.7)</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Procedure characteristic &#x02013; specified by the procedure side.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Left side </th><th align="center" colspan="2" rowspan="1">Right side</th></tr><tr><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">Mean (interval)</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">Mean (interval)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CFA minimum diameter (mm)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">7.8 (5 &#x02013; 10)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">7.8 (4 &#x02013; 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFA calcification</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0</td><td align="center" rowspan="1" colspan="1">37 (30.1)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">46 (37.4)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 50%</td><td align="center" rowspan="1" colspan="1">72 (58.5)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">59 (48)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 50%</td><td align="center" rowspan="1" colspan="1">14 (11.4)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">18 (14.6)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of access sites &#x02265; 12 F</td><td align="center" rowspan="1" colspan="1">60 (48.8)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">112 (91.1)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Sheath size</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">11.2 (6 &#x02013; 24)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">17.0 (6 &#x02013; 26)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 18 F</td><td align="center" rowspan="1" colspan="1">89 (72.4)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">23 (18.7)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 18 F</td><td align="center" rowspan="1" colspan="1">34 (27.6)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">99 (80.5)</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CFA=common femoral artery</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Acute major vascular access complication.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="80%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="center" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bleeding that needed vascular intervention or
transfusion</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Limb ischemia - Acute arterial
dissection/occlusion</td><td align="center" rowspan="1" colspan="1">2 (1.62%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute pseudoaneurysm</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Infection</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table></table-wrap><p>There were no cases of vessel puncture site hematoma and only one patient required a
perioperative blood transfusion, which was unrelated to the access site (<xref ref-type="table" rid="t4">Table 4</xref>).</p><p>One patient presented a minor late complication (<xref ref-type="table" rid="t5">Table 5</xref>) detected on a routine angiotomography in the postoperative
period (three months after the procedure). It was a small (0.4 cm) asymptomatic
pseudoaneurysm at the puncture site in the right CFA. The patient is being followed
with Doppler ultrasound and angiotomography, with no symptoms or increase in size up
to a 18-month follow-up period. This was a TEVAR with a 20 F sheath in a 72 year old
woman with good sizes (7.5 mm) and not very calcified (&#x0003c; 50%) access vessels.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Late complications after 30 days - angiotomography</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="80%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Complications</th><th align="center" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Arterial thrombosis</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Arterial dissection</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Pseudoaneurysm</td><td align="center" rowspan="1" colspan="1">1 (0.81%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stenosis &#x0003e; 30%</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Arteriovenous fistula</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematoma</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table></table-wrap><p>In three patients the Perclose Proglide&#x000ae; could not be delivered at the first
attempt, since it did not crossed the anterior wall. In these situations, we simply
removed the device and inserted another one over the short wire, with success at the
second attempt in all cases.</p><p>Pairwise comparisons revealed increased major access complication among patients with
&#x0003e;50% CFA calcification <italic>vs.</italic> none (<italic>P</italic>=0.004) and
&#x0003e; 50% CFA calcification <italic>vs.</italic> &#x0003c; 50% CFA calcification
(<italic>P</italic>=0.002). Small artery diameter (&#x0003c;6.5 mm) also increased
major access complication compared to bigger diameters (&#x0003e;6.5 mm)
(<italic>P</italic>=0.027). Other possible predictors of major access
complications were analyzed and can be seen in <xref ref-type="table" rid="t6">Table
6</xref>.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Risk factors for major vascular access complications. Univariate
analysis.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic </th><th align="center" rowspan="1" colspan="1">Major complication</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (complication <italic>vs</italic>. no
complication)</td><td align="center" rowspan="1" colspan="1">76.63 &#x000b1;9.6 <italic>vs</italic>. 84&#x000b1;8.5
years</td><td align="center" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" rowspan="1" colspan="1">Female <italic>vs</italic>. male gender</td><td align="center" rowspan="1" colspan="1">1/47 (2.12%) <italic>vs</italic>. 0/76</td><td align="center" rowspan="1" colspan="1">0.816</td></tr><tr><td align="left" rowspan="1" colspan="1">CFA calcification</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="4" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0</td><td align="center" rowspan="1" colspan="1">0/33</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;50%</td><td align="center" rowspan="1" colspan="1">0/70</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;50%</td><td align="center" rowspan="1" colspan="1">2/20 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFA diameter (mm)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="3" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;6.5</td><td align="center" rowspan="1" colspan="1">2/21 (9.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;6.5</td><td align="center" rowspan="1" colspan="1">0/102</td></tr><tr><td align="left" rowspan="1" colspan="1">Introducer</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="3" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;18 F</td><td align="center" rowspan="1" colspan="1">0/15</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;18 F</td><td align="center" rowspan="1" colspan="1">2/108 (1.9%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CFA=common femoral artery</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The first multicenter randomized controlled trial published by Nelson et
al.<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> included 151
patients undergoing EVAR using either the Prostar XL or Perclose Proglide&#x000ae;
(PEVAR) <italic>versus</italic> standard cutdown of the CFA endovascular repair
(CEVAR). Their study demonstrated a technical success rate of 96% with the use of
Perclose Proglide&#x000ae;, which was similar to our findings.</p><p>With a trend towards less invasive approach, a recent study comparing EVAR with PEVAR
showed a technical success rate of 96% in PEVAR patients, a significantly shorter
total operation time, a shorter length of hospital stay, and fewer wound
complications in patients who were treated with PEVAR<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>In our study we used the same definition of access-related complications as used in
the PEVAR trial. As our main goal was to evaluate the results of vascular closure
device and complications with large sheaths, several aortic pathologies such as
aneurysms and transcatheter aortic valve implantation were included.</p><p>A high rate of success in device deployment (98.37%) was found, as well as a small
number of complications. Furthermore, these complications were more restricted to
our initial learning curve (cases number 7, 11 and 35). In our series, there were
two (1.61%) major vascular complications, both were acute vascular occlusion, which
were successfully treated with immediate open repair (cases number 11 and 35). There
was only one (0.81%) minor late complication (a small 0.4 cm asymptomatic
pseudoaneurysm which has been followed for 18 months - case number 11). This
corresponds to 0.82% of vascular accesses in our series with Perclose&#x000ae;.</p><p>Even though our objective wasn&#x02019;t to compare PEVAR with Surgical Endovascular Repair
(SEVAR), is worth to remember that the PEVAR trial demonstrated a significant
advantage over the PEVAR treatment regarding major ipsilateral access site vascular
sequelae in 30 days (6% <italic>vs.</italic> 10%; <italic>P</italic>=0.0048).
However, for minor ipsilateral access site vascular sequelae, the authors found
similarity between the groups (4% <italic>vs.</italic> 8%;
<italic>P</italic>=0.6777).</p><p>Three (2.43%) patients could not use the device at the first attempt. The needles
didn&#x02019;t cross the arterial wall and when we pull to cut the first thread. We simply
removed the entire device and inserted another one, with success in all three cases.
This could be due to some device defect; or, more probably, to CFA calcification -
wall stiffness impeding the needle to cross the arterial wall; or to fibrosis around
the artery. It did not compromise percutaneous closure success. This, per se, was
not considered a failure because another device was introduced and adequate
hemostasis was obtained in all patients.</p><p>We also demonstrate that the percutaneous closure is safe and effective in a clinical
series with a short operative time and no wound complications in PEVAR patients. Our
average length of unit intensive care (ICU) stay was 24&#x000b1;14.25 hours and our
average length of hospital stay was 3&#x000b1;3.1 days.</p><p>Prior published reports success rates for PEVAR varying from 71% to 100%<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>. In addition to access vessel diameter and type of closures
device, femoral artery calcification, access vessel tortuosity and depth of CFA and
groin scars have all been associated with PEVAR failure<sup>[<xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Some previous studies have shown that the success rate is significantly related to
the caliber of the sheath<sup>[<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Lee et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> demonstrated that large sheaths
had low technical success rates among the subset of sheath sizes. Kim et
al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> also found seven
of eight closure procedure failures in cases involving sheaths over 18 F and
believed that procedural failure might be related to large sheath sizes. Sheath size
&#x02265; 18 F is considered as a possible predictor of percutaneous vascular
complications in PEVAR, and this is why these complications occur more often in
thoracic stent grafts, which usually use delivery sheaths larger than 18 F. In other
review articles<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup> the CFA diameter was considered another predictor
of vascular failure. Similarly to these studies, we also demonstrated that &#x0003e; 50%
CFA calcification and &#x0003c; 6.5 mm CFA diameter were predictive of major
complications. In our study, both patients that had acute vascular complications
were female, had 18 F or bigger sheath and small (6.5 mm) and calcified (&#x0003e;50%)
access vessels. The association of big sheath (&#x02265;18 F) and small vessels with
calcification is believed to be a bad combination for percutaneous approach.</p><p>In one meta-analysis, the quality of the artery was found to be a greater predictor
of failure than the sheath size itself<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The use of the Perclose Proglide&#x000ae; device is not
considered when the CFA has a large plaque (&#x0003e; 50% circumference) or ring-shape
calcification. Patients with &#x0003e; 50% anterior wall calcification had a higher
failure rate than patients without calcification<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p><p>All of our patients that had acute vascular complications (2 - 1.62%) had more than
2/3 CFA calcifications. Based on this experience, in the case of severe
calcification (&#x0003e; than 2/3 and anterior plaque), we would prefer a CFA cutdown or
an alternative access instead. It was made clear that the association of small
femoral or iliac arteries (&#x0003c;6.5 mm), severe calcification (&#x0003e; than 2/3
particularly in the anterior wall) and tortuosity is bad for any femoral access,
especially for PEVAR.</p><p>During midterm follow-up vascular complications such as infection, thrombosis,
stenosis, occlusion or pseudoaneurysm are rare<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. All of our patients were followed clinically and with an
angiotomography for vascular access evaluation analyzed independently by a
radiologist and a surgeon, with just one (0.81%) patient presenting with a small (4
mm) asymptomatic pseudoaneurysm that is being followed every 6 months with
imaging.</p><p>The American Heart Association currently recommends the use of femoral artery closure
devices to achieve faster hemostasis, shorter duration of bed rest, and possibly
improved patient comfort<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>The preclosure technique is now widely used and started with a 10 F ProStar&#x000ae;
XL (Abbott Laboratories, Abbott Park, Il, USA). More recently the use of multiple 6
F Perclose Proglide&#x000ae; devices has been recommended for bigger sheaths. The
ProStar&#x000ae; XL, which was the first reported closure device for PEVAR<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, has several disadvantages compared
with multiple Perclose Proglide&#x000ae;. First, the ProStar&#x000ae; XL requires more
extensive subcutaneous dissection to insert. Second, the mechanism of deployment is
complicated, and failure of hemostasis could occur early in the experience (learning
curve). Third, a braided suture may have increased the potential for infections. The
Perclose Proglide&#x000ae; has a small profile (6 F) and a simple deployment
mechanism with a monofilament (prolene 3-0) suture very similar to surgical arterial
suture. We started using the Perclose Proglide&#x000ae; and we have no experience
with the ProStar&#x000ae; XL.</p><p>Total percutaneous access with the use of Perclose Proglide&#x000ae; in our experience
showed to be effective, with a very few complications in the setting of PEVAR for
the treatment of several aortic and aortic valve pathologies. Recently, the use of
just one Perclose Proglide&#x000ae;, in order to reduce costs, has been reported with
very good results<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>.</p><sec><title>Limitations</title><p>This study has some limitations. It was a retrospective, nonrandomized and
observational study with a relatively small number of patients at a single
center. Our findings should be prospectively confirmed with a larger
population.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The preclosure technique with two Perclose Proglide&#x000ae; for PEVAR proved to be
safe and effective. There was no mortality related to the technique in our series
and two acute femoral artery complications that were more restricted to our initial
learning curve and required prompt vascular intervention. Both patients were female,
had small (6.5 mm) and more than 50% CFA calcification and these three situations
predicted vascular access complications.</p><p>With a very meticulous technique, well-trained surgeon and careful patient selection,
total percutaneous approach to endovascular treatment for several aortic diseases is
safe and less invasive than CFA cutdown. The mortality and morbidity of PEVAR were
low, but longer follow-up is necessary.</p><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">EKS</td><td align="left" rowspan="1" colspan="1">Conception and study design; realization of operations;
analysis and/or data interpretation; statistical analysis;
manuscript redaction or critical review of its content; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MS</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RS</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APT</td><td align="left" rowspan="1" colspan="1">Conception and study design; realization of operations;
analysis and/or data interpretation; statistical analysis; final
manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BM</td><td align="left" rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Hospital de Cl&#x000ed;nicas de Porto Alegre
(HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS,
Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Jneid</surname><given-names>H</given-names></name><name><surname>Derdeyn</surname><given-names>CP</given-names></name><name><surname>Klein</surname><given-names>LW</given-names></name><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Lookstein</surname><given-names>RA</given-names></name><etal/></person-group><person-group person-group-type="author"><collab>American Heart Association Diagnostic and Interventional Cardiac
Catheterization Committee of the Council on Clinical Cardiology</collab><collab>Council on Cardiovascular Radiology and Intervention</collab><collab>Council on Peripheral Vascular Disease</collab><collab>Council on Cardiovascular Surgery and Anesthesia.and Stroke
Council</collab></person-group><article-title>Arteriotomy closure devices for cardiovascular procedures a
scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2010</year><volume>122</volume><issue>18</issue><fpage>1882</fpage><lpage>1893</lpage><pub-id pub-id-type="pmid">20921445</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>PC</given-names></name><name><surname>Krajcer</surname><given-names>Z</given-names></name><name><surname>Diethrich</surname><given-names>EB</given-names></name></person-group><article-title>Closure of large percutaneous access sites using the Prostar XL
Percutaneous Vascular Surgery device</article-title><source>J Endovasc Surg</source><year>1999</year><volume>6</volume><issue>2</issue><fpage>168</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">10473335</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>PR</given-names></name><name><surname>Kracjer</surname><given-names>Z</given-names></name><name><surname>Kansal</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Bianchi</surname><given-names>C</given-names></name><name><surname>Hashemi</surname><given-names>H</given-names></name><etal/></person-group><article-title>A multicenter, randomized, controlled trial of totally
percutaneous access versus open femoral exposure for endovascular aortic
aneurysm repair (the PEVAR trial)</article-title><source>J Vasc Surg</source><year>2014</year><volume>59</volume><issue>5</issue><fpage>1181</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">24440678</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>DB</given-names></name><name><surname>Karthaus</surname><given-names>EG</given-names></name><name><surname>Soden</surname><given-names>PA</given-names></name><name><surname>Ultee</surname><given-names>KH</given-names></name><name><surname>van Herwaarden</surname><given-names>JA</given-names></name><name><surname>Moll</surname><given-names>FL</given-names></name><etal/></person-group><article-title>Percutaneous versus femoral cutdown access for endovascular
aneurysm repair</article-title><source>J Vasc Surg</source><year>2015</year><volume>62</volume><issue>1</issue><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">25827969</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petronelli</surname><given-names>S</given-names></name><name><surname>Zurlo</surname><given-names>MT</given-names></name><name><surname>Giambersio</surname><given-names>S</given-names></name><name><surname>Danieli</surname><given-names>L</given-names></name><name><surname>Occhipinti</surname><given-names>M</given-names></name></person-group><article-title>A single-centre experience of 200 consecutive unselected patients
in percutaneous EVAR</article-title><source>Radiol Med</source><year>2014</year><volume>119</volume><issue>11</issue><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">24700151</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenack</surname><given-names>M</given-names></name><name><surname>Umscheid</surname><given-names>T</given-names></name><name><surname>Tessarek</surname><given-names>J</given-names></name><name><surname>Torsello</surname><given-names>GF</given-names></name><name><surname>Torsello</surname><given-names>GB</given-names></name></person-group><article-title>Percutaneous endovascular aortic aneurysm repair a prospective
evaluation of safety, efficiency, and risk factors</article-title><source>J Endovasc Ther</source><year>2009</year><volume>16</volume><issue>6</issue><fpage>708</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">19995109</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WA</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name><name><surname>Nelson</surname><given-names>PR</given-names></name><name><surname>Huber</surname><given-names>TS</given-names></name><name><surname>Seeger</surname><given-names>JM</given-names></name></person-group><article-title>Midterm outcomes of femoral arteries after percutaneous
endovascular aortic repair using the Preclose technique</article-title><source>J Vasc Surg</source><year>2008</year><volume>47</volume><issue>5</issue><fpage>919</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">18328666</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousa</surname><given-names>AY</given-names></name><name><surname>Abu-Halimah</surname><given-names>S</given-names></name><name><surname>Nanjundappa</surname><given-names>A</given-names></name><name><surname>AbuRahma</surname><given-names>AF</given-names></name><name><surname>Richmond</surname><given-names>BK</given-names></name></person-group><article-title>Current update on the status of totally percutaneous aneurysm
repair</article-title><source>Vasc Endovascular Surg</source><year>2013</year><volume>47</volume><issue>6</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">23922309</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensley</surname><given-names>RP</given-names></name><name><surname>Hurks</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Pomposelli</surname><given-names>F</given-names></name><name><surname>Hamdan</surname><given-names>A</given-names></name><name><surname>Wyers</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ultrasound-guided percutaneous endovascular aneurysm repair
success is predicted by access vessel diameter</article-title><source>J Vasc Surg</source><year>2012</year><volume>55</volume><issue>6</issue><fpage>1554</fpage><lpage>1561</lpage><pub-id pub-id-type="pmid">22360918</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousa</surname><given-names>AY</given-names></name><name><surname>Campbell</surname><given-names>JE</given-names></name><name><surname>Broce</surname><given-names>M</given-names></name><name><surname>Abu-Halimah</surname><given-names>S</given-names></name><name><surname>Stone</surname><given-names>PA</given-names></name><name><surname>Hass</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Predictors of percutaneous access failure requiring open femoral
surgical conversion during endovascular aortic aneurysm
repair</article-title><source>J Vasc Surg</source><year>2013</year><volume>58</volume><issue>5</issue><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">23810299</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teh</surname><given-names>LG</given-names></name><name><surname>Sieunarine</surname><given-names>K</given-names></name><name><surname>van Schie</surname><given-names>G</given-names></name><name><surname>Goodman</surname><given-names>MA</given-names></name><name><surname>Lawrence-Brown</surname><given-names>M</given-names></name><name><surname>Prendergast</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Use of the percutaneous vascular surgery device for closure of
femoral access sites during endovascular aneurysm repair lessons from our
experience</article-title><source>Eur J Vasc Endovasc Surg</source><year>2001</year><volume>22</volume><issue>5</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">11735179</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadis</surname><given-names>GS</given-names></name><name><surname>Antoniou</surname><given-names>GA</given-names></name><name><surname>Papaioakim</surname><given-names>M</given-names></name><name><surname>Georgakarakos</surname><given-names>E</given-names></name><name><surname>Trellopoulos</surname><given-names>G</given-names></name><name><surname>Papanas</surname><given-names>N</given-names></name><etal/></person-group><article-title>A meta-analysis of outcome after percutaneous endovascular aortic
aneurysm repair using different size sheaths or endograft delivery
systems</article-title><source>J Endovasc Ther</source><year>2011</year><volume>18</volume><issue>4</issue><fpage>445</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">21861729</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlert</surname><given-names>P</given-names></name><name><surname>Eggebrecht</surname><given-names>H</given-names></name><name><surname>Erbel</surname><given-names>R</given-names></name><name><surname>Sack</surname><given-names>S</given-names></name></person-group><article-title>A modified "preclosure" technique after percutaneous aortic valve
replacement</article-title><source>Catheter Cardiovasc Interv</source><year>2008</year><volume>72</volume><issue>6</issue><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">19006257</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakko</surname><given-names>J</given-names></name><name><surname>Scali</surname><given-names>S</given-names></name><name><surname>Beck</surname><given-names>AW</given-names></name><name><surname>Klodell</surname><given-names>CT</given-names><suffix>Jr</suffix></name><name><surname>Beaver</surname><given-names>TM</given-names></name><name><surname>Martin</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Percutaneous thoracic endovascular aortic repair is not
contraindicated in obese patients</article-title><source>J Vasc Surg</source><year>2014</year><volume>60</volume><issue>4</issue><fpage>921</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">24845111</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Applegate</surname><given-names>RJ</given-names></name></person-group><article-title>Vascular closure device failure we are getting better but not
there yet</article-title><source>JACC Cardiovasc Interv</source><year>2012</year><volume>5</volume><issue>8</issue><fpage>845</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">22917456</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WA</given-names></name><name><surname>Brown</surname><given-names>MP</given-names></name><name><surname>Nelson</surname><given-names>PR</given-names></name><name><surname>Huber</surname><given-names>TS</given-names></name></person-group><article-title>Total percutaneous access for endovascular aortic aneurysm repair
("Preclose" technique)</article-title><source>J Vasc Surg</source><year>2007</year><volume>45</volume><issue>6</issue><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">17398056</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>YG</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name></person-group><article-title>Efficacy and safety of the preclose technique following
percutaneous aortic stent-graft implantation</article-title><source>J Endovasc Ther</source><year>2013</year><volume>20</volume><issue>3</issue><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">23731308</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manunga</surname><given-names>JM</given-names></name><name><surname>Gloviczki</surname><given-names>P</given-names></name><name><surname>Oderich</surname><given-names>GS</given-names></name><name><surname>Kalra</surname><given-names>M</given-names></name><name><surname>Duncan</surname><given-names>AA</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Femoral artery calcification as a determinant of success for
percutaneous access for endovascular abdominal aortic aneurysm
repair</article-title><source>J Vasc Surg</source><year>2013</year><volume>58</volume><issue>5</issue><fpage>1208</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">23830310</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihashi</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Ohte</surname><given-names>N</given-names></name></person-group><article-title>Safety and utility of total percutaneous endovascular aortic
repair with a single Perclose ProGlide closure device</article-title><source>J Vasc Surg</source><year>2016</year><volume>63</volume><issue>3</issue><fpage>585</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">26506938</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Procedure characteristic.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">Mean (interval)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Procedure type</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;TEVAR</td><td align="center" rowspan="1" colspan="1">17 (13.7%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;TAAA</td><td align="center" rowspan="1" colspan="1">4 (3.2%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EVAR</td><td align="center" rowspan="1" colspan="1">44 (33.5%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;TAVI</td><td align="center" rowspan="1" colspan="1">59 (47.6%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedure time (minutes)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">70 (20 &#x02013; 190)</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU time (hours)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">28.5 (12 &#x02013; 48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay (days)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">3.8 (2 &#x02013; 35)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood transfusion</td><td align="center" rowspan="1" colspan="1">1 (0.8)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">CFA minimum diameter (mm)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">7.8 (4 &#x02013; 10)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFA calcification</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0</td><td align="center" rowspan="1" colspan="1">83 (35)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264; 50%</td><td align="center" rowspan="1" colspan="1">131 (55.3)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 50%</td><td align="center" rowspan="1" colspan="1">32 (9.7)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of access site &#x02265; 12 F</td><td align="center" rowspan="1" colspan="1">172 (69.9)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Sheath size</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 18 F</td><td align="center" rowspan="1" colspan="1">112 (45.7)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265; 18 F</td><td align="center" rowspan="1" colspan="1">133 (54.3)</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>EVAR=endovascular repair for abdominal aortic aneurysms; TEVAR=thoracic
endovascular repair; TAAA=thoracoabdominal aortic aneurysms;
TAVI=transcatheter aortic valve implantation; CFA=common femoral artery;
ICU: Intensive care unit</p></fn></table-wrap-foot></table-wrap></floats-group></article>